weed message board

Smoking weed outside of coffee shops – zandvoort – The Netherlands Forum

Smoking weed outside of coffee shops – zandvoort

  • United Kingdom Forums
  • United States Forums
  • Europe Forums
  • Canada Forums
  • Asia Forums
  • Central America Forums
  • Africa Forums
  • Caribbean Forums
  • Mexico Forums
  • South Pacific Forums
  • South America Forums
  • Middle East Forums

Staying in Zandvoort for a few days.

Travelling alone with a child.

Would love to indulge in a small smoke to help me through the stresses of travelling alone – obviously not around my child – hopefully when he is in bed.

Do hotels frown upon smoking on balconies?

Also – would I be able to purchase any without actually going inside a coffee shop? Could I purchase in the outdoor area of the shop?

Is smoking on beaches (well away from others) do-able? Or is this a no no?

Please don’t pounce on me – I’m trying not to offend!

Answer 11 of 13: Staying in Zandvoort for a few days. Travelling alone with a child. Would love to indulge in a small smoke to help me through the stresses of travelling alone – obviously not around my child – hopefully when he is in bed. Do hotels frown…

Canopy Growth Corporation (WEED.TO)

Previous Close 32.21
Open 32.00
Bid 31.30 x 0
Ask 31.45 x 0
Day’s Range 31.30 – 32.14
52 Week Range 12.96 – 38.22
Volume 675,544
Avg. Volume 1,864,948
Market Cap 11.66B
Beta (5Y Monthly) 2.31
PE Ratio (TTM) N/A
EPS (TTM) -4.28
Earnings Date Feb 09, 2021
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 27.55
Fair Value

Subscribe to Premium to view Fair Value for WEED.TO

Related Research

High-Risk Sundial Growers Worth a Look after the Pullback

A few weeks back, I said to fade the big rally in Sundial Growers (NASDAQ:SNDL). But now, after its pullback from 75 cents to 45 cents per share, there may be opportunity in SNDL stock for those with a high risk appetite. No, not due to the fact this penny stock has fallen further below $1 per share. It’s still a work-in-progress, but there’s a pathway for this beaten-down pot stock to deliver in 2021.InvestorPlace – Stock Market News, Stock Advice & Trading Tips As InvestorPlace’s Sarah Smith wrote Dec. 21, 2020, recent restructuring means the company is now debt-free. Yes, this deal was dilutive to Sundial shareholders. But, said dilution may be worth it, if it gives the company more breathing room to executive their pivot toward a retail-based business model. Like I said before, I wouldn’t buy this as a U.S. pot legalization play. Even with a more liberal U.S. president entering the White House, this too remains a work in progress. But, while not probable, legalization remains possible in 2021. Any hint things are moving towards an open U.S. pot market will be enough to send this stock parabolic yet again. Grading 10 of 2020’s Hottest SPACs in Preparation for the New Year Yes, valuation remains a concern. Much of its potential is already priced into shares. But, given how high shares could climb if just one of its catalysts comes to fruition, it may be worth the risk. Treating this stock like a call option, those willing to risk big losses could stand to generate epic gains on a small position. SNDL Stock and What Lies Ahead There are three things that could change the game for Sundial in 2021. Firstly, the company’s turnaround plan pays off. Specifically, its move out of wholesale and into retail. Per the November investor presentation, it’s largely made this leap, with 77% of its sales mix coming from branded cannabis sales. Secondly, the potential for big changes to U.S. federal pot laws. Sure, the recent bill to decriminalize marijuana will likely go nowhere in the U.S. Senate. But, with things moving in the right direction, you can’t count out 2021 being the year a fully legal marijuana market opens up from coast to coast. Any sort of major federal pot law change will send pot stocks parabolic once again. Especially smaller names like Sundial. Thirdly, the potential for M&A in the Canadian cannabis space. Following the announced merger between Aphria (NASDAQ:APHA) and Tilray (NASDAQ:TLRY), we could see further consolidation in this sector. That’s not to say Sundial is a takeover target. But, a merger between this company and another similarly-sized competitor could bring about economies of scale that could create a fast path toward profitability. Yet, while each of these factors could put more points into SNDL stock, I agree valuation remains a concern. Even after the recent pull-back, upside remains priced-in. But, given speculators trade this on headlines and momentum, don’t split hairs over its forward multiple. Instead, view this as an option on the industry’s improving prospects in 2021. Treat This Like an Option, Not Like a Stock Selling for 7 times estimated 2020 sales of $54.9 million, Sundial is far from being a value play. Even when taking into account projected sales through 2029, this looks more like a stock that will “grow into its valuation.” That is to say, hold steady at today’s prices. But, not generate additional gains for investors from here. But, in the near term, shares could still move higher. With speculators buying on potential rather than fundamentals, it won’t take much to send shares surging yet again. Much of this has to do with the stock’s penny stock status. Appearing “cheap” to retail investors, shares are vulnerable to wild speculation and high volatility. Until the company executes a reverse stock-split (which InvestorPlace’s Muslim Farooque recently said is likely), expect this to remain the case. Now, I know this sounds more like gambling than investing. But again, the best way to play SNDL stock is to treat it like an option. If the legalization or turnaround catalysts come to fruition, expect big gains from today’s prices. If not? Expect big losses, but manageable if you take a small position. Simply put, like with other pot stocks, you have to read the room. Shares will move higher (or lower) based on news, not on valuation metrics. Don’t Bet the Ranch, But There’s Potential Upside Stronger pot plays, like Canopy Growth (NASDAQ:CGC) remain the best vehicle for exposure to the legalization megatrend. But, although an “also ran,” there’s still opportunity with Sundial at today’s prices. As long as you treat this more like an option rather than a stock. Don’t bet the ranch with SNDL stock. The risk of heavy losses remains very high. But, as a small position, shares could take off once again, if some of the above-mentioned catalysts come to fruition in 2021. On the date of publication, Thomas Niel did not (either directly or indirectly) hold any positions in the securities mentioned in this article. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post High-Risk Sundial Growers Worth a Look after the Pullback appeared first on InvestorPlace.

6 Cannabis Stocks to Buy as the U.S. Softens Its Stance

Aside from inspiring a whole lotta bad puns I’ve had to weed from my system, cannabis stocks have also piqued my interest greatly. The sector remains young and full of potential, yet more dependent on legislators to guarantee its success than any other I can name. This stems from the fact that marijuana use, while fully legal in 15 states and partially legal another 33, is still against the law on the federal level. (It is also illegal in Idaho though potatoes, a principal ingredient in vodka, are not. Just sayin’.) Until Congress approves decriminalization and the president signs it into law, cannabis stocks may have something of a cloud hanging over them, and not of the Cheech and Chong kind. The good news is that under a new administration this could be one step closer to reality, as Vice President-elect Kamala Harris was the Senate sponsor of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act. The House version came within inches of a vote on the week of Sept. 21. Regardless of what happens in Washington D.C., pot stocks are hot and cannabis is big business. It’s estimated that the sector could generate up to $130 billion annually into the U.S. economy by 2024. It’s safe to assume that before then, more states will approve recreational use, just as New Jersey, Arizona, South Dakota and Montana did on Election Day 2020. Remarkably, marijuana was illegal all across the U.S. until 2012, when Colorado became the first state to legalize it. InvestorPlace – Stock Market News, Stock Advice & Trading Tips Thanks in part to action north of the border — Canada legalized pot in 2018 — the marijuana sector has picked up steam over the last 24 months. 7 of 2020’s Most Interesting Electric Vehicle SPACs — Good and Bad This list of cannabis stocks includes companies and contenders that stand on the cusp of maximizing the sector’s untapped potential. Canopy Growth Corp. (NYSE:CGC) TerrAscend (OTCMKTS:TRSSF) GrowGeneration Corp. (NASDAQ:GRWG) Cara Therapeutics (NASDAQ:CARA) Merck & Co. (NYSE:MRK) Sanofi (NASDAQ:SNY) Yes, it’s fair to say these stocks are “poised to grow” without my getting arrested by the Pun Police. It’s a good thing, too, as some federal officials consider bad pot jokes a Class A misdemeanor. And so, onto the list and I promise — no pot shots. Marijuana stocks: Canopy Growth Corp. (CGC) Source: Shutterstock Among cannabis stocks, CGC has faced crisis and survived, a crucial plus given that it belongs to a sector where many companies remain untested. Based in Smith Falls, Canada, Canopy ran into problems with less-than-expected domestic demand, distribution problems, and the one-two punch of losses and light revenue. All this stoked the ire of Constellation Brands (NYSE:STZ), which owns a 38% stake in CGC and forced the ouster of co-founder and co-CEO Bruce Linton. The company has since recovered nicely, and year over year, CGC stock is up 35%. As of Dec. 21, the company announced some big moves that it hopes will prepare it for the new year. First, it retired its ownership interest in Canopy Rivers, which helped it develop key greenhouse infrastructure. At the same time, Canopy Growth increased its direct conditional stake in another Canadian marijuana company, TerrAscend from about 13% to 21%. CGC stock also has a celebrity name going for it. While Marta Stewart is better known for hanging pots than hawking pot, Canopy has changed all that. She’s the doyenne behind Martha Stewart CBD brands and as such, represents a key entry point into the U.S. market. TerrAscend (TRSSF) Source: Shutterstock As long as we’re on the subject of TerrAscend, let’s note that this Toronto-area company is worth a look on its own as cannabis stocks go. TRSSF stock is up 440% year over year, and that includes a 57% spike since Nov. 1. What’s the deal with this outfit that has a presence far beyond Ontario province? For our purposes, it’s essential to know that TerrAscend has some strong roots in the U.S. It claims to be the first cannabis company with sales here. It also operates businesses such as The Apothecarium, a cannabis dispensary with several retail locations in California. Canopy Growth’s move to buy up TRSSF stock could ultimately bolster both companies. Yes, investors should take care to make sure Canopy’s days of mismanagement are behind it. But with 11 brands under its umbrella, TerrAscend has legs to stand on. The 7 Safest Stocks to Start Off 2021 on the Right Foot As cannabis stocks go, it’s poised to ride the tailwind of legalization in America. GrowGeneration Corp. (GRWG) Source: Shutterstock Based in Denver, GrowGeneration may have a relatively small market capitalization at $2.2 billion. But in 2020, it’s made many investors wealthy as GRWG stock has rocketed more than 900%! Though of course, the question is how long a high (ugh!) such as this can last. No question, GRWG stock is overvalued with a price-to-earnings ratio over 500. (This figure shows how many dollars an investor will spend to buy $1 of company profit.) But as new sectors explode — electric vehicles provide a textbook example — profits aren’t as important as momentum, and GrowGeneration clearly has plenty of that. I like that this company is based in Colorado, the first state to fully legalize pot. It has been in business since 2008. Burgeoning sectors too often attract wannabes and fly-by-night concerns; GrowGeneration is neither of these. That said, new investors in GRWG stock should watch closely, as the overvaluation could spell bubble trouble in 2021. Cara Therapeutics (CARA) Source: Shutterstock That CARA stock is relatively flat year over year should relieve investors. The March market dip caused by the novel coronavirus, also known at the “Covid-19 Crash,” sent shares tumbling to a 52-week low of $9.12. They now trade at a healthier $15.15, which gives the Connecticut-based company breathing room to cross the finish line with Korsuva, its cannabis-based therapeutic. Korsuva goes after an obscure disease known as chronic kidney disease-associated pruritus (CKD-aP), which is characterized by pain and itching. Giddy with prospect of the drug’s eventual approval, investors sent shares soaring last year but have since grown impatient. But those with attention spans beyond investor lemmings will note that on Dec. 28, Cara announced that it had submitted a New Drug Application to the FDA. If granted, that would kick-off a six-month review process with Korsuva’s approval coming as early as Summer 2021. 9 Long-Term Stocks for the Next Decade Those who get in now could ride a mighty big wave of investor enthusiasm in the months ahead. Merck & Co. (MRK) Source: Atmosphere1 / What’s a nice big pharma like Merck doing on a pot stocks list like this? Lest you conjure images of well-heeled suits lighting up in the executive washroom, consider this. The New York-area company has made a veritable stealth entrance into the cannabis stock club. It now holds 35 cannabis-related patents. MRK stock investors should know the company’s interest lies in high-end medical applications, and in May 2019 it entered into an agreement with Intec Pharma Ltd. (NASDAQ:NTEC). Together, the companies are collaborating on a medication, now in phase-3 trials, that uses cannabinoids to treat symptoms in advanced Parkinson’s disease patients. Year over year, MRK stock hasn’t done so hot; it’s down almost 12%. But since the Covid-19 crash, it has shot up over 15%. Currently, 7 of 8 analysts on TipRanks call Merck a buy, making it definitively overweight in the field of cannabis stocks. Sanofi (SNY) Source: nitpicker / The one overseas player on this list, Paris-based Sanofi, tipped down 5% year over year. That’s not so bad given all the pandemic pandemonium. But part of it is the company’s own doing. News broke in early December that a lab mistake with its Covid-19 vaccine candidate would set back delivery by four to five months. Still, Sanofi stock remains profitable for investors. Rewind two years and it’s up 12% overall. Look ahead to 2021 and you’ll see some tremendous potential as cannabis stocks go. It holds 39 medical cannabis patents, second worldwide only to Abbvie (NYSE:ABBV), which has 59. As for what those patents mean in the short term, investors will have to sit tight. 8 Stocks to Buy for the ‘Inevitable’ Market Crash There’s no news of anything in the pipeline just yet, though in 2019 Sanofi entered into an agreement with Opiant Pharmaceuticals (NASDAQ:OPNT) to manufacture drinabant, a drug used to treat acute cannabinoid overdose (ACO). On the date of publication, Lou Carlozo did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Stance appeared first on InvestorPlace.

Constellation Stock Can Still Rocket Higher. Here’s Why.

The sale of the company’s lower-price wine and spirits portfolio is slated to close the first week of 2021.

CGC Stock: Is The Biggest Marijuana Stock A Buy As Rivals Merge?

Canopy Growth faces greater competition from a potential merger between Aphria and Tilray. Is Canopy Growth stock a buy?

Top Marijuana Stocks on the NASDAQ for January 2021

These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and the most momentum for January.

Should You Buy Marijuana Stocks After House Passes MORE Act?

Are marijuana stocks a good buy amid the coronavirus pandemic? The marijuana industry gets lots of hype, but pot stocks have poor fundamentals and technicals.

Luminar Technologies Struggles to Find Its Direction in December

Luminar Technologies (NASDAQ:LAZR), the lidar-sensor maker, entered December trading at $24 on a one-way ticket to $40. Unfortunately, it hit a major speed bump a few days after its Dec. 3 public debut. LAZR stock fell from a 52-week high of $47.80 all the way to a low of $22.32 before rebounding slightly the closer we’ve gotten to the end of the year. The first hit to its share price came on Dec. 9. That was due to profit-taking and the news that competitor Innoviz was merging with Collective Growth (NASDAQ:CGRO), a special purpose acquisition company headed by former Canopy Growth (NASDAQ:CGC) CEO Bruce Linton.InvestorPlace – Stock Market News, Stock Advice & Trading Tips The second hit came on Dec. 15 when Intel (NASDAQ:INTC) subsidiary Mobileye suggested that it might develop its own lidar units rather than partnering with Luminar. December has been a crazy first month of trading for the automotive company. However, it appears that the stock has bottomed, and aggressive investors have bought on the dip. 7 Undervalued Stocks That Could Soar in 2021 As I write this, it’s trading at over $37. Should you buy before it heads back to $40 or waits for it to return to the low $20s? I’ll look at both arguments. LAZR Stock Is Ready to Return to $40 Not everyone thinks Luminar is overvalued at $40. Northland analyst Gus Richard recently suggested that the price decline after the Mobileye news was nothing to fear but fear itself. “1) We do not believe an internal lidar system could be ready for 2025 production. 2) LAZR will be the entrenched supplier to Mobileye by that time. 3) Intel is developing lidar, and we believe INTC’s SiP group has other priorities. 4) If Mobileye had an internal solution ready to go they would not have announced a deal with LAZR,” Tipranks reported on Dec. 16. Richard suggests that it would take Intel the better part of five years and as much as $1 billion to develop its own internal lidar system suitable for autonomous driving taxis. As a result of the stock’s price decline, Richard upgraded LAZR stock to outperform from market perform with a target price of $41. Can you say $50? Here at InvestorPlace, contributor Louis Navellier discussed buying on the dip on Dec. 14. Although LAZR has regained the losses from the Mobileye news and then some, it is still down nearly 11% from its 52-week high. As Navellier suggests, a bet on LAZR is a bet on lidar technology and the idea that self-driving vehicles will someday become the norm benefiting Luminar Technology shareholders. It’s not a ridiculous argument to make. Luminar Is a Better Buy Near $20 In 2019, Luminar lost $94.7 million on $12.6 million in revenue. It estimates revenues will grow to $15 million in 2020 with an operating loss of $72 million, both slightly better than a year ago. However, I don’t think there’s any doubt based on the here and now that it’s expensive at almost 600 times sales. To get to $40, you’ve got to use a lot of imagination. InvestorPlace’s Larry Ramer believes that it is astoundingly overpriced. He believes that if you do want to get in on the action for companies supplying sensors for autonomous driving, Velodyne (NASDAQ:VLDR) is a much better buy. Based on annualized total sales of $103.4 million, it’s trading at a much more reasonable 33 times sales. Ramer goes on to suggest that short-seller Citron Research believes LAZR has a much better chance of falling back to $20 than it does, revisiting $40. Further, Velodyne’s diversification makes it a much safer risk in terms of margin of safety. He believes Luminar should not be bought above $20. The Bottom Line In September, I recommended LAZR because I liked its potential and the possibility of hitting $800 million in sales by 2025. At the time, it was trading around $12 and had just announced its combination with the Gores Metropoulos SPAC. Fast forward three months and it’s completed its combination and had a wild first month trading as a public company. While I understand what Ramer is saying about Velodyne, I still feel like Luminar’s story is more interesting, which will ultimately provide it with a much larger valuation. I wouldn’t put a lot of money into LAZR. However, if you can buy it in the low $20s and afford to lose 100% of your investment, the upside potential is significant. On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Luminar Technologies Struggles to Find Its Direction in December appeared first on InvestorPlace.

A centuries old icon meets modern day innovation with the Lexus HX Sleigh Concept

Running on 100% renewable holiday spirit, Santa’s newest team member features the latest in Lexus Hybrid Electric Technology * Designed by Elite Takumi Elves * Unlimited Cargo Capacity * All-Reindeer Drive (ARD) Enables Powerful and Smooth Dashing Through Snow * A 25″ Touchscreen Display with Embedded Air Traffic Control provides the most relaxing drive December 24th has ever seen NORTH POLE, Arctic, Dec. 21, 2020 /CNW/ – This year, as families stare up at the dazzling night sky, they may notice a flash of red flying by.

Canopy Growth Stock: Is The Biggest Marijuana Stock A Buy As Top Rivals Merge?

Canopy Growth faces greater competition from a potential merger between Aphria and Tilray. Is Canopy Growth stock a buy?

Canopy Growth Announces Plan of Arrangement with Canopy Rivers

SMITHS FALLS, ON, Dec. 21, 2020 /CNW/ – Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC) today announced that it has entered into an arrangement agreement (the “Arrangement Agreement”) with its wholly-owned subsidiary The Tweed Tree Lot Inc.

First agreement for YUL bar and restaurant workers

Seniority and recall rights to be protected for 24 months during the pandemicMONTREAL, Dec. 17, 2020 /CNW Telbec/ – While most of the 240 new unionized workers at Dorval Airport’s bars and restaurants have been laid off due to the COVID-19 pandemic, their jobs will remain intact and protected for 24 months, and these employees will continue to receive group insurance coverage during this period.

This Week On Benzinga Cannabis Hour: Canopy VP Sol Clahane; Delta 9 Chief John Arbuthnot; Copperstate Farms CEO Pankaj Talwar

Sol Clahane, vice president and general manager at Canopy Growth Corp. (NYSE: CGC), is the latest cannabis pro to join the Benzinga Cannabis Hour.And the timing couldn’t be more perfect.These days, she’s overseeing major CBD brand and partnership initiatives such as the one Canopy just completed with “Domestic Diva” Martha Stewart.Before joining the Smith Falls, Canada-based company, Clahane was shaking things up in the beverage space at Pernod Ricard, Coca-Cola Co. (NYSE: KO) and PepsiCo (NASDAQ: PEP).This week, Clahane will join co-hosts Patrick Lane and Elliot Lane alongside special guests Delta 9 (OTCQX: VRNDF) CEO John Arbuthnot and Copperstate Farms CEO Pankaj Talwar.Click here to tune in. Last Week For those of you who missed out on last week’s episode, tune in below:Special guests included: * Nick Paschal: CEO, Alpine IQ West Paschal: VP of Sales * Alpine IQ Karen Mayberry: Co-Founder & CMO * Rob Tankson: Co-Founder & COO, PrestoDoctorThe Benzinga Cannabis Hour is produced every week and brings together top executives, entrepreneurs, and experts from all corners of the cannabis industry. Each show features three or more guests from a broad spectrum of expertise in cannabis.To tune in, stream the episode below; click subscribe on the official Benzinga YouTube channel; or visit Hour is also published on most major podcasting platforms, including Spotify, Google Podcasts, Breaker, Pocket Casts, and more.See more from Benzinga * Click here for options trades from Benzinga * Saucey Founder: ‘It Sucks’ That Weed Is Illegal In NY, But Big Plans In Play For ‘East Coast Brand’ * Entourage Effect’s Matt Hawkins To Cannabis Operators: ‘Put Egos Aside’ To Get Deals Done(C) 2020 Benzinga does not provide investment advice. All rights reserved.

Aphria, Tilray To Form Cannabis Giant Amid U.S. Legalization Hopes

Aphria and Tilray announced a merger Wednesday that would create the biggest weed company by revenue.

I admit it — these are my 5 dumbest investment calls of 2020

Jeff Reeves says he was wrong about COVID-19’s impact on the S&P 500, about marijuana stocks, about bitcoin and more.

Tilray shares surge 25% on merger with Aphria to create world’s largest cannabis company

Tilray and Aphria plan to merge to create the world’s largest cannabis company.

Why Marijuana Stocks Were on Fire Today

Marijuana stocks closed Tuesday trading broadly higher — and the smaller they were, the higher they popped. Tiny HEXO (NYSE: HEXO) closed the day up 7.9%, while Aurora Cannabis (NYSE: ACB) rose 6.8%, and industry bellwether Canopy Growth (NASDAQ: CGC) closed out the day with a 5.8% gain. Why did marijuana stocks rise today?

This elite Israeli army squad member is behind a startup going public in a $1.4 billion SPAC deal

Innoviz looks to make a splash in the Lidar sensor market.

Polytechnique Montréal: firmly committed to sustainable engineering

MONTRÉAL, Dec. 15, 2020 /CNW Telbec/ – Polytechnique Montréal announced today the creation of the Institute on Sustainable Engineering and Net Zero Economy (IIDEC – Institut de l’ingénierie durable et de l’économie carboneutre) whose focus will be solving environmental and social challenges associated with issues of sustainable economic development.

Could Canopy Growth Be a Millionaire-Maker Stock?

After all, marijuana is an in-demand product in an expanding multinational industry that has plenty of room to innovate, and there’s no single company that has enough power to box out the other competitors from a share of the profit. The biggest reason Canopy isn’t a millionaire-maker stock is that it hasn’t demonstrated the kind of revenue and earnings growth that would make that possible. Unfortunately, like many other cannabis companies, Canopy’s ability to consistently turn a profit is anything but proven, and so its price hasn’t exploded alongside its rising income from sales.

Legalization May Be Years Away, So Steer Clear of Tilray

Prospects may be improving for pot stocks. But, this alone is hardly reason to buy Tilray (NASDAQ:TLRY). After soaring after election day, Tilray stock pulled back. And with good reason. While the incoming U.S. presidential administration wants to decriminalize marijuana, full on legalization/commercialization remains years away. Source: Jarretera / Until laws are changed on the federal level, Canada-based pot companies like Tilray can’t enter the U.S. market. With this catalyst fading, I don’t see shares delivering more gains in the coming year. But, there are two other reasons why I’m more bearish on this pot play, as opposed to stronger ones like Canopy Growth (NASDAQ:CGC). Firstly, its weak growth prospects. While sales could improve in the coming quarters as the company focuses on more profitable business lines, I’m not holding my breath. Secondly, Tilray’s balance sheet remains a hot mess. Even after recent debt conversions, more dilutive transactions may be required.InvestorPlace – Stock Market News, Stock Advice & Trading Tips Put it all together, and this remains an “also ran” pot stock that belongs in your “avoid” pile. Sure, with high short interest, a squeeze could send shares parabolic once again. But, that’s a hardly a reason to be bullish. Tilray Stock and the U.S. Legalization Timeline Like with other pot stocks, speculators buying the headlines dived back into this name, on the heels of Joe Biden’s electoral victory. With Biden, and his running mate, Kamala Harris, pledging to decriminalize marijuana, more progressive pot policies are on the horizon. 8 Battery Stocks That Electric Vehicle Companies Rely On Yet, that doesn’t mean we’ll be able to buy joints at the local convenience store within the next four years. That is to say, the timeline for full pot legalization remains many years away. Sure, with the U.S. House of Representatives voting for the MORE Act, at least decriminalization is making headway. But, this proposed legislation likely won’t get through the still Republican-controlled U.S. Senate. With even decriminalization still a work in progress, full-on legalization in the near term remains a pipe dream. With this big catalyst falling onto the back burner, it’s hard to see Tilray stock moving any higher than where it trades today (around $8.35 per share). And, with other negative factors at play, we could see shares move back to prior price levels (around $5 per share). Other Factors Could Push Shares Lower A delayed U.S. pot legalization timeline isn’t the only reason why Tilray shares could give up more of their recent gains. The company’s weak growth prospects, and overleveraged balance sheet, are key issues as well. In the quarter ending Sept. 30, sales were flat compared to the prior year’s quarter. But, part of this was due to its discontinuation of bulk sales. Adult use sales surged 25.9% compared to Q3 2019. And, that wasn’t the only silver lining. Refocusing its efforts toward higher-margin products, the company managed to narrow its losses. For the next quarterly earnings release, Tilray has some big expectations to live up to. Not only are analysts projecting revenue slightly above this quarter’s sales levels. The company itself anticipates finally getting to positive or breakeven non-GAAP EBITDA. The question is, can they deliver? It’s possible. But, the issue here may be that last month’s run-up may already price this potential into shares. And, if the company fails to achieve this goal? Expect shares to give up most, if not all, of these gains. However, that’s not the only factor that could drive shares lower from here. As I discussed, Tilray’s balance sheet remains a hot mess. Sure, convertible debt transactions of $124.3 million and $72.9 million, respectively, converted much of this debt into equity. Yet, with these transactions came substantial shareholder dilution. Cutting the pie into many more slices, potential gains from here may be limited. To top it all off, dilution may not be over just yet. With around $278 million in debt still outstanding, and continued losses, something’s got to give. Avoid This ‘Also Ran’ Pot Stock With full-on U.S. federal legalization still years away, it’s hard to see Tilray making any more gains from today’s price levels. And, with the company’s growth and balance sheet issues, it’s easy to see shares holding onto their recent gains, as post-election enthusiasm for this and other pot stocks starts to fade. Granted, with high short-interest in Tilray shares, a squeeze could be in the cards. With around 22% of its outstanding shares sold short, just a breadcrumb of positive news could send shares soaring yet again, as bears cover their positions. Yet, the potential for a short squeeze doesn’t make the bull case for Tilray stock. With better pot plays (like Canopy) out there, it’s best to avoid this “also ran” pot stock. On the date of publication, Thomas Niel did not (either directly or indirectly) hold any positions in the securities mentioned in this article. Thomas Niel, a contributor to InvestorPlace, has written single stock analysis since 2016. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Legalization May Be Years Away, So Steer Clear of Tilray appeared first on InvestorPlace.

Canopy Growth Stock Is a Bet on a U.S. Market Which May Not Arrive

Cannabis stocks are hot again, and industry leader Canopy Growth (NASDAQ:CGC) has benefited. Before a 5% pullback on Wednesday, CGC stock had better than doubled in a little over two months. Even with the one-day weakness, shares are up 37% year-to-date. Source: Shutterstock It’s been a long time coming. The sector as a whole topped out back in March of 2019, when CGC briefly cleared $50. Since then, consistently disappointing results in Canada, as well as a lack of movement elsewhere in the world, have undercut sentiment. In fact, the 40%-plus decline in CGC stock from its March 2019 peak is relatively minimal compared to a 90%-plus plunge for Aurora Cannabis (NYSE:ACB) and an 85% fall for Hexo (NYSE:HEXO), to name just two struggling rivals. But sentiment has turned, at least for now. And it’s U.S. politics that appear to be the catalyst. Positive results in the November elections along with long-awaited movement at the federal level are sparking hopes of full legalization. Canopy, more so than perhaps any other Canadian producer, would be a big winner in that scenario.InvestorPlace – Stock Market News, Stock Advice & Trading Tips The problem after the rally, however, is that the case for Canopy stock and the sector as a whole increasingly rests on that U.S. market. We’ve seen enough, or at least close to enough, to believe that other regulated markets (whether recreational or medical) simply do not and cannot offer the profits required to support even current valuations. That leaves CGC stock vulnerable to sentiment toward U.S. legalization. Of late, that’s been a plus for the stock. At some point, that’s likely to change. The Turnaround Begins There is a sense that Canopy itself is in the middle of a potentially successful turnaround. That sense isn’t completely wrong. 8 Battery Stocks That Electric Vehicle Companies Rely On Canopy brought in David Klein from shareholder Constellation Brands (NYSE:STZ,NYSE:STZ.B) to improve execution. He’s done so. Layoffs have significantly lowered operating expenses and cash burn. Production has been rationalized, with Canopy this week announcing the closure of more production facilities. Canopy, like so many other Canadian producers, simply overshot. The demand in Canada and elsewhere was not there to support the vast amount of production capacity put into place. Significant oversupply led to a lack of pricing power and crushed profit margins. The company at least is taking steps to try and fix that problem. Meanwhile, Canopy still is investing behind its business, as it should. CBD (cannabidiol) products have been launched in Canada and the U.S. According to Canopy’s fiscal second quarter earnings release last month, the company is gaining market share, with a 200 basis point improvement in Q2 to 15.5% from 13.5% the quarter before. Indeed, revenue in the quarter was an all-time record for Canopy. That growth came with lower spending, as Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) loss narrowed sharply year-over-year. Operating expenses declined 19% y-o-y, while gross margin expanded signficantly. As I wrote at the beginning of the year, the hope coming into 2020 was that Klein would make Canopy Growth a better company. It certainly seems like he’s succeeding. The market is responding as such: CGC stock rallied almost 5% after earnings. Is It Enough? And yet there’s a real question as to whether ‘better’ is good enough. Taking a step back and reviewing the Q2 report, it’s hard to answer in the affirmative. Revenue did grow. Adjusted EBITDA loss did narrow. But the quarter remains something close to a disaster. Canopy generated 135 million CAD in revenue. Adjusted EBITDA was negative 85.7 million CAD. Canopy, using the most favorable possible profit metric, still lost 63 cents for every dollar in sales. Free cash flow burn, at over 190 million CAD, dwarfed revenue. Yes, the Canadian market is relatively new. But it’s not that new. “Cannabis 2.0” products have been rolled out. Retail stores have opened after regulatory bottlenecks slowed capacity. There should be a way to at least near profitability in this market. Canopy is nowhere close. The rest of the world isn’t contributing enough, either. International medical revenue actually declined 3% year-over-year. And so it’s exceedingly difficult to see how this business, outside of the U.S., can support a market capitalization now back over $10 billion. Net cash of 1.2 billion CAD (roughly $940 million) obviously isn’t enough. The profits required to support that valuation have to come somewhere, and it’s hard to see that ‘somewhere’ being anywhere but the U.S. The U.S. and CGC Stock Now, if the U.S. does come around, Canopy has a huge opportunity. The likes of Aurora are hamstrung by balance sheet problems. Canopy has a deal with Acreage Holdings (OTCMKTS:ACRHF) that could provide for almost-instant access to a federally regulated American market. But there are two core reasons for caution. The first is that Canopy isn’t necessarily just going to waltz in and take market share. Existing multi-state operators like Trulieve Cannabis (OTCMKTS:TCNNF) already have strong presences and valuable brands. The second is that federal legalization is not a slam dunk. And it’s legalization, not just decriminalization, that almost certainly would be required for a company like Canopy to have the needed access to financial and other resources. The U.S. House of Representatives did vote on cannabis decriminalization last week, but it was largely a symbolic vote. Republicans in the Senate still likely have enough power to block any legislation, and Joe Biden has said that he does not support full legalization. State-level elections did provide some support for legalization and decriminalization — but, again, that’s not enough. Canopy needs movement at the federal level to enter the U.S. And it needs to enter the U.S. to create the profits needed to move CGC stock higher. That entry could still be many, many years off. And when investors realize that fact, the rally in CGC stock is likely to reverse. On the date of publication, Vince Martin did not have (either directly or indirectly) any positions in the securities mentioned in this article. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post Canopy Growth Stock Is a Bet on a U.S. Market Which May Not Arrive appeared first on InvestorPlace.

Is CGC A Good Stock To Buy Now?

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]

Canopy Growth and TerrAscend’s Arise Bioscience Enter Debt Financing Agreement

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and Arise Bioscience Inc. (“Arise”), a wholly owned subsidiary of TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF) engaged only in the legal sale of CBD products, today announced they have entered into a loan financing arrangement in the amount of US$20 million (the “Loan”) pursuant to a secured debenture (the “Debenture”). In connection with the Loan, TerrAscend has issued 2,105,718 common share purchase warrants to the Company (the “Warrants”).

Find the latest CANOPY GROWTH CORPORATION (WEED.TO) stock quote, history, news and other vital information to help you with your stock trading and investing.